ESTRO 2023 - Abstract Book

S1209

Digital Posters

ESTRO 2023

Conclusion Given the results of the present preliminary analysis which reports a high recurrence rate, it remains of relevant importance to continue to offer potentially curative salvage treatment. In the PSMA-PET and WB-MRI era, and the ability to detect potentially distant metastatic disease so early, it becomes crucial to select patients for such examination based on criteria and clinical stratification. The present and future analyses on an enlarged dataset, based on a retrospective experience will lay the foundation for better understanding how to target care in this patient setting.

PO-1492 Ultra Hypo RT in elderly PCa patients with aggressive disease: still a space for curative approach?

G. Corrao 1 , G. Marvaso 1 , C. Lorubbio 1,2 , F. Mastroleo 1 , M.G. Vincini 1 , C. Fodor 1 , I. Repetti 1,2 , V. Pierini 1 , G.C. Mazzola 1 , C. Pedone 1 , D. Zerini 1 , B.A. Jereczek-Fossa 1,2 1 IEO, European Institute of Oncology, IRCCS, Division of Radiation Oncology , Milan, Italy; 2 University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy Purpose or Objective Longer life expectancy has led to a significant increase in the number of elderly patients localized PCa candidates for curative RT. Patients aged ≥ 75 years often present a high prevalence of comorbidities and it makes difficult to propose RT including both prostate and pelvis associated with long-term androgen deprivation therapy (ADT), as recommended by NCCN guidelines. The aim of the present study (Ethical Committee approval number UID 2684) is to evaluate the efficacy and safety of personalized ultra hypofractionated RT (UHRT) +/- ADT in this cohort of patients. Materials and Methods Elderly men aged ≥ 75 years with unfavorable intermediate to high-risk localized PCa who underwent UHRT on prostate between 2012 and 2018 were identified and analyzed. Continuous variables were summarized as mean/median and